Skip to main content
. 2021 Oct 14;28(5):4157–4166. doi: 10.3390/curroncol28050352

Figure 5.

Figure 5

(a) Comparison of response to atezolizumab + bevacizumab combination therapy in pretreatment low neutrophil-to-lymphocyte ratio (NLR) and high NLR groups (CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease). (b) Comparison of progression-free survival in the low and high NLR groups.